Synapse - Works

Results (115372)

Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation

Meeting Abstract

Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
Blood (2022)

Fulltext@MSK | Save

Incidence, clinical associations, and co-mutation patterns of UBA1 mutations in MDS

Meeting Abstract

Sirenko, M.; Bernard, E.; Beck, D. B.; Creignou, M.; Domenico, D.; Farina, A.; Arango, J. E.; Kosmider, O.; Hasserjian, R. P.; Jadersten, M.; more...
Blood (2022)

Fulltext@MSK | Save

Pelabresib (CPI-0610) as add-on to ruxolitinib in myelofibrosis: Durability of response and safety beyond week 24 in the phase 2 MANIFEST study

Meeting Abstract

Harrison, C.; Kremyanskaya, M.; Bose, P.; Gupta, V.; Rampal, R. K.; Lambert, J.; Talpaz, M.; Vannucchi, A.; Kuykendall, A.; Kiladjian, J. J.; more...
Blood (2022)

Fulltext@MSK | Save

Five-year overall survival analysis using first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase in a prospective observational study (SIMPLICITY)

Meeting Abstract

Mauro, M.; Paquette, R.; Hehlmann, R.; Williams, L. A.; Goldberg, S. L.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D.; DeGutis, I. S.; McBride, A.; more...
Blood (2022)

Fulltext@MSK | Save

Clinical response to azacytidine (AZA) is associated with increased contribution from mutated blood progenitors: Insights from single cell genotyping of matched stem/progenitor and mature blood cells from MDS/CMML patients pre- and post-AZA treatment

Meeting Abstract

Thoms, J. A. I.; Schnegg-Kaufmann, A.; Bhuyan, G. S.; Hampton, H. R.; Vaughan, L.; Rutherford, K.; Kakadia, P. M.; Lee, H. M.; Johansson, E.; Failes, T. W.; more...
Blood (2022)

Fulltext@MSK | Save

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Final results of a phase Ib/II randomized study and single-arm extension (Ext) study

Meeting Abstract

Sehn, L. H.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A. K.; Özcan, M.; Safar, V.; more...
Blood (2022)

Fulltext@MSK | Save

A risk model for CML patients with COVID-19: Importance of molecular response in the context of age, comorbidities and country income

Meeting Abstract

Radich, J. P.; Kok, C. H.; Chelysheva, E. Y.; Cortes, J. E.; Jiang, Q.; Mauro, M.; Milojkovic, D.; Moiraghi, B.; Nicolini, F. E.; Ongondi, M.; more...
Blood (2022)

Fulltext@MSK | Save

Enitociclib (VIP152/formerly BAY1251152) is a selective and active CDK9 inhibitor : Preliminary safety and early signs of efficacy in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)

Meeting Abstract

Shadman, M.; Mato, A. R.; Batlevi, C. L.; Flinn, I. W.; Gutierrez, M.; Uemura, M.; Stevens, D. A.; Morillo, D.; Byrd, J. C.; Frigault, M. M.; more...
Blood (2022)

Fulltext@MSK | Save

Safety and efficacy of splenic irradiation for non-Hodgkin lymphoma

Meeting Abstract

Hubbeling, H.; Imber, B. S.; Wijetunga, N. A.; Tringale, K. R.; Hajj, C.; Yahalom, J.
Blood (2022)

Fulltext@MSK | Save

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: Interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C)

Meeting Abstract

Lee, H. J.; Abramson, J. S.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Eva, D. D.; Hess, B. T.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
Blood (2022)

Fulltext@MSK | Save